



Lartruvo® (olaratumab) – Product withdrawal

- On April 25, 2019, [Eli Lilly announced](#) the withdrawal of [Lartruvo \(olaratumab\)](#) injection from the market.
 - Lartruvo is being withdrawn from the market following the failure of the phase 3 [ANNOUNCE](#) clinical trial, in which Lartruvo did not improve survival for patients.
 - No new patients should receive Lartruvo outside of participation in ongoing clinical trials.
 - Eli Lilly is establishing a program to ensure current patients will have access to Lartruvo with limited interruption after it is withdrawn from the market.
- The FDA approved Lartruvo, in combination with [doxorubicin](#), for the treatment of adult patients with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
 - Lartruvo was approved under the FDA's accelerated approval program in October 2016. As a condition of approval, Eli Lilly conducted a larger study, designed to confirm the clinical benefit of Lartruvo in these patients.
- Eli Lilly will provide more information regarding this withdrawal program directly to healthcare professionals in the coming weeks.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.